Recent News

• 11.10.2025 - electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
• 11.05.2025 - electroCore Announces Third Quarter 2025 Financial Results
• 10.23.2025 - electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025
• 10.03.2025 - electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
• 10.03.2025 - electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
• 10.03.2025 - electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
• 09.30.2025 - gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
• 09.30.2025 - gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
• 09.30.2025 - gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
• 09.29.2025 - electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium

Recent Filings

• 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2025 - EX-99.1 EX-99.1
• 11.05.2025 - 8-K Current report
• 10.24.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 10.17.2025 - D Notice of Exempt Offering of Securities
• 10.17.2025 - D Notice of Exempt Offering of Securities
• 10.03.2025 - S-3 Registration statement under Securities Act of 1933
• 10.03.2025 - 8-K Current report